Post transplant erythrocytosis in hypercalcemic renal transplant recipients

American Journal of Transplantation

Volumn 3, Issue 7, 2003, Pages 873-877

  Kurella, Manjula ^a   Butterly, David W ^b   Smith, Stephen R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Calcium; Hypercalcemia; Kidney transplant; Post transplant erythrocytosis

Indexed keywords

CALCITRIOL; CALCIUM; ERYTHROPOIETIN; PARATHYROID HORMONE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHI SQUARE TEST; ERYTHROCYTOSIS; FEMALE; HEMATOCRIT; HUMAN; HYPERCALCEMIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATION; PREDICTION; RECIPIENT; UNITED STATES;

EID: 0038351911     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00131.x     Document Type: Article

References (25)

1. Wickre CG, Norman DJ, Bennison A, Barry JM, Bennett WM. Postrenal transplant erythrocytosis. A review of 53 patients. Kidney Int 1983; 23: 731-737.
2. Qunibi WY, Barri Y, Devol E, al-Furayh O, Sheth K, Taher S. Factors predictive of post-transplant erythrocytosis. Kidney Int 1991; 40: 1153-1159.
3. Perazella MA, Bia MJ. Posttransplant erythrocytosis: case report and review of newer treatment modalities. J Am Soc Nephrol 1993; 3: 1653-1659.
4. Gaston RS, Julian BA, Barker CV, Diethelm AG, Curtis JJ. Enalapril: safe and effective therapy for posttransplant erythrocytosis. Transplant Proc 1993; 25: 1029-1031.
5. Danovitch GM, Jamgotchian NJ, Eggena PH et al. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism. Transplantation 1995; 60: 132-137.
6. Midtvedt K, Stokke ES, Hartmann A. Successful long-term treatment of post-transplant erythrocytosis with losartan. Nephrol Dial Transplant 1996; 11: 2495-2497.
7. Mrug M, Stopka T, Julian BA, Prchat JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 2310-2314.
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
9. Sauron C, Berthoux P, Berthoux F et al. New insights and treatment in posttransplant polycythemia (erythrocytosis) of renal recipients. Transplant Proc 1993; 25: 1032-1033.
10. Kessler M, Hestin D, Mayeux D, Mertes PM, Renoult E. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study. Clin Nephrol 1996; 45: 83-89.
11. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13: 551-558.
12. Carozzi S, Ramello A, Nasini MG et al. Ca++ and 1,25(OH)2D3 regulate in vitro and in vivo the response to human recombinant erythropoietin in CAPD patients. Adv Perit Dial 1990; 6: 312-315.
13. Kelsey SM, Newland AC, Cunningham J et al. Sustained haematological response to high-dose oral alfacalcidol in patients with myelodysplastic syndromes. Lancet 1992; 340: 316-317.
14. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Schohn D, Chuet C. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 514-518.
15. Torres A, Rodriguez AP, Concepcion MT et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998; 13 (Suppl. 3): 94-97.
16. Hercz G, Pei Y, Greenwood C et al. Aplastic osteodystrophy without aluminum: the role of 'suppressed' parathyroid function. Kidney Int 1993; 44: 860-866.
17. Miller BA, Cheung JY, Tillotson DL, Hope SM, Scaduto RC Jr. Erythropoietin stimulates a rise in intracellular-free calcium concentration in single BFU-E derived erythroblasts at specific stages of differentiation. Blood 1989; 73: 1188-1194.
18. Cheung JY, Zhang XQ, Bokvist K, Tillotson DL, Miller BA. Modulation of calcium channels in human erythroblasts by erythropoietin. Blood 1997; 89: 92-100.
19. Miller BA, Barber DL, Bell LL et al. Identification of the erythropoietin receptor domain required for calcium channel activation. J Biol Chem 1999; 274: 20465-20472.
20. Carozzi S, Grazia Nasini M, Salit M, Cantaluppi A, Nocera A, Valente U. Ca (++) -induced modulation of erythropoiesis in polycythemic transplanted patients. Transplant Proc 1991; 23: 1309-1311.
21. Stockenhuber F, Geissler K, Sunder-Plassmann G et al. Erythrocytosis in renal graft recipients due to a direct effect of cyclosporine. Transplant Proc 1989; 21: 1560-1562.
22. Klaassen RJ, van Gelder T, Rischen-Vos J, Deinum J, Man in't Veld AJ, Weimar W. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis. Transplantation 1997; 64: 780-782.
23. Julian BA, Brantley RR, Jr., Barker CV et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9: 1104-1108.
24. Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 1995; 26: 495-500.
25. Gupta M, Miller BA, Ahsan N et al. Expression of angiotensin II type I receptor on erythroid progenitors of patients with post transplant erythrocytosis. Transplantation 2000; 70: 1188-1194.